tbuckley/cabot-search huggingface dataset:
Droplet Digital PCR Analysis for Diagnosis and Minimal Residual Disease Monitoring in Adult Ph+ Acute Lymphoblastic Leukemia
Authors: Nicoletta Coccaro, Antonella Zagaria, Luisa Anelli, Giuseppina Tota, Paola Orsini, Claudia Brunetti, Luciana Impera, Angela Minervini, Crescenzio Francesco Minervini, Cosimo Cumbo, Angelo Cellamare, Paola Casieri, Domenico Pastore, Paola Carluccio, Giorgina Specchia, Francesco Albano
Journal: Blood (2015)
Role Of Sf3b1 On Hematopoiesis
Authors: Manabu Matsunawa, Ryo Yamamoto, Masashi Sanada, Aiko Sato, Yusuke Shiozawa, Kenichi Yoshida, Yasunobu Nagata, Ayana Kon, Tetsuichi Yoshizato, Makoto Otsu, Kyoichi Isono, Haruhiko Koseki, Hiromitsu Nakauchi, Seishi Ogawa
Journal: Blood (2013)
Restoration of Bone Balance Via Activin a Inhibition Results in Anti-Myeloma Activity
Authors: Sonia Vallet, Siddhartha Mukherjee, Nileshwari Vaghela, Samantha Pozzi, Loredana Santo, Diana Cirstea, Mariateresa Fulciniti, Aliyah Rahemtullah, Eyal Attar, Alexander R Guimaraes, Wanling Xie, Chirayu Patel, Jesse Schoonmaker, Edie Weller, Teru Hideshima, Nikhil C. Munshi, Jas Seehra, David T. Scadden, Kenneth C Anderson, Noopur Raje
Journal: Blood (2008)
BMET-02EVALUATION OF DIFFERENT THERAPEUTIC MODALITIES FOR PRIMARY TREATMENT AND SALVAGE THERAPY AND THEIR RELATIVE COST IN PATIENTS WITH BRAIN METASTASES: A SINGLE INSTITUTION REPORT
Authors: Pascal Bahary, David Roberge, Carole Lambert, Laura Masucci, Jean-Paul Bahary
Journal: Neuro-Oncology (2015)

BACKGROUND: Indications for whole brain radiotherapy (WBRT), stereotaxic radiosurgery (SRS) and craniotomy are not sufficiently well defined in a context of optimal care that takes into account cost effectiveness of therapy. Previous reports have shown contradictory results with regards to optimal care. Some favor loco-regional control while others preservation of neuro-cognitive function. We decided to review our own experience and trends in treatment with analysis focused not only on survival but as well treatment costs and use of salvage therapy. METHODS: Between January 2010 and 2015, we have treated 387 consecutive patients treated for brain metastasis. Chart review will collect the type of initial treatment as well as the type and the number of salvage treatment. The patients will be identified according to anatomic primary site and histology, age and gender, the date of initial diagnosis, performance status, number of brain metastasis and presence of other systemic metastasis. Local control and survival will be analyzed using the Kaplan Meier method, while age, gender, primary site location and initial method of treatment will be studied with COX univariate and multivariate analysis. Treatment cost for every patient will also be evaluated. RESULTS: Data analysis will be done between June and July 2015 and the results will be presented at the San Antonio SNO meeting.
Prognostic implication of the maximum standardized uptake value (mSUV) on <sup>18</sup>F FDG-PET in patients with metastatic hepatocellular carcinoma
Authors: D. Shin, S. Han, D. Oh, S. Im, T. Kim, Y. Bang
Journal: Journal of Clinical Oncology (2009)

e15531 Background: The role of 18 F-fluorodeoxyglucose-positron emission tomography ( 18 F FDG- PET) in hepatocelluar carcinoma (HCC) has not been firmly established. We conduct this study to investigate the value of mSUV on 18 F FDG-PET as a prognostic factor in HCC, especially in metastatic setting. Methods: We consecutively enrolled HCC patients with extrahepatic metastatic lesions, who have been evaluated with 18 F FDG-PET before palliative anticancer treatment, between January 2000 and June 2008 at the Seoul National University Hospital. We retrospectively analyzed the clinical outcome and the value of mSUV as a prognostic factor. Results: A total of 57 patients (male, 86.0%) were enrolled. Median age was 57 years (range, 36–78). Hepatitis B was the predominant cause of HCC (82.5%), followed by non-viral hepatitis (14.0%) and hepatitis C (3.5%). Most patients (94.7%) were Child-Pugh A and 3 patients (5.3%) were Child-Pugh B. The most commonly involved site was lung (47%), bone (26%), and LN (33%). Median serum AFP level was 68ng/ml (range, 2–48000) and the median mSUV was 4.1 (range, 0.5–57.0). Forty patients (70.2%) received systemic chemotherapy, 14 patients (24.6%) received palliative radiotherapy, 23 patients (40.4%) received palliative surgery, and 7 patients (12.3%) received TACE. In univariate analysis of overall survival (OS), patients with mSUV over 4.0, AFP over 400ng/ml, and presence of intrahepatic viable lesion, and no palliative surgery showed significantly shorter OS (p=0.007, p=0.006, p&lt;0.001, p=0.02, respectively). In multivariate analysis of OS, mSUV over 4.0, AFP over 400ng/ml, and presence of intrahepatic viable lesion were independent prognostic factors (p=0.01, p=0.01, p&lt;0.001, respectively). In patients with mSUV &gt; VS &lt;4.0 or AFP &gt; VS &lt;400ng/ml, there was no difference of palliative anticancer treatment pattern. When combined mSUV with AFP, the OS of patients with mSUV &gt;4.0 and AFP&gt;400ng/ml VS mSUV &lt;4.0 or AFP&lt;400ng/ml VS mSUV &lt;4.0 and AFP&lt;400ng/ml was 11.0 months vs 16.0 months vs 35.7 months, respectively (p=0.006). Conclusions: The mSUV on 18 F FDG-PET is a prognostic factor for OS in patients with metastatic HCC. The combined analysis of mSUV with AFP can have a more potent prognostic impact. No significant financial relationships to disclose.
NIMG-13QUANTITATIVE MR TEXTURE ANALYSIS CAN IDENTIFY LOW GRADE GLIOMA AND PERITUMORAL WHITE MATTER FROM NORMAL APPEARING WHITE MATTER (NAWM) PHENOTYPES
Authors: Aikaterini Kotrotsou, Pascal O. Zinn, Masumeh Hatami, Rivka Colen
Journal: Neuro-Oncology (2015)

BACKGROUND: To assess the efficacy of texture analysis (TA) in differentiating Low Grade Gliomas (LGGs) from Normal Appearing White Matter (NAWM) in a cohort of brain cancer patients using T2-FLAIR MR images.Also the impact of the number of gray-levels employed was investigated.METHODS: T2-FLAIR and post-gadolinium (GD) contrast T1-weighted MR images of 11 TCGA patients (mean age 40.8 years, range 27-59.5 years) were retrospectively analyzed.All patients were diagnosed with LGGs Overall survival
Phase II trial of bevacizumab and lenalidomide with docetaxel and prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC).
Authors: Bamidele Adesunloye, Xuan Huang, Yangmin M. Ning, Ravi A. Madan, James L. Gulley, Melony Beatson, Paul Gustav Kluetz, David Adelberg, Philip M. Arlen, Howard L. Parnes, Marcia Mulquin, Seth M. Steinberg, John Joseph Wright, Jane B. Trepel, Nancy Ann Dawson, Clara Chen, Andrea Borghese Apolo, William Douglas Figg, William L. Dahut
Journal: Journal of Clinical Oncology (2012)

207 Background: Angiogenesis may be vital to mCRPC. Previously, we had shown the potent anti−tumor activity of dual antiangiogenic therapy by combining thalidomide (T) and bevacizumab (B) with docetaxel (D) and prednisone (P) in mCRPC (Ning JCO 2010). We hypothesized that combining lenalidomide (L), an analogue of T, with B, D, and P would have a more favorable efficacy/toxicity profile. Methods: All patients (pts) had chemotherapy−naïve mCRPC. 3 pts received R 15 mg daily, 3 pts had 20 mg daily, and the rest had 25 mg daily for 14 days of every 21−day cycle (C). All pts received D 75 mg/m2 and B 15 mg/kg on day 1 with P 10 mg and enoxaparin daily throughout each C. Pegfilgrastim was given on day 2. PSA was assayed each C with imaging after C2 and then after every 3C. Results: 47 of the planned 51 pts have been enrolled. Median age was 66 (51−82), Gleason score 8 (5−10), on−study PSA 91.6 ng/ml (0.15−3520), pre−study PSA doubling time 1.43 months (0.52−6.73), number of Cs 14 (1−31), and PFS was 19.3 months as of this analysis. Among 45 pts who have completed ≥2 cycles, 39 (86.7%) and 30 (66.7%) had PSA declines of ≥50% and ≥75%, respectively. Of 29 pts with measurable disease there were 2 CR, 21 PR, and 6 SD (79.3% overall RR). 10/47 pts were taken off study for radiographic disease progression and 5/47 for other reasons. Grade ≥3 toxicities included neutropenia (24/47), anemia (9/47), thrombocytopenia (5/47), weight loss (1/47), hypertension (3/47), and febrile neutropenia (4/47). Other toxicities included perianal fistula (3/47), rectal fissure (1/47), myocardial infarction (1/47), and osteonecrosis of the jaw (ONJ) (16/47, 34.0%). At the time of diagnosis of ONJ, 9/16 pts were on bisphosphonates and 3/16 had used bisphosphonates previously. Although the incidence of ONJ was higher than the 18.3% reported by Ning, a recent study of carboplatin plus weekly docetaxel reported an incidence of 29.3%. Conclusions: Dual antiangiogenic therapy with, B and L, plus D and P was associated with high PSA (86.7%) and tumor (79.3%) responses with manageable toxicities. Further studies are underway to explore the high incidence of ONJ.
Salvage Therapy with Azacitidine Increases Regulatory T Cells in Patients with AML or MDS and Early Relapse After Allogeneic Blood Stem Cell Transplantation
Authors: Thomas Schroeder, Julia Fröbel, Ron Patrick Cadeddu, Akos G. Czibere, Ariane Dienst, Esther Zipperer, Uwe Platzbecker, Gesine Bug, Lutz Uharek, Roland Fenk, Ulrich Germing, Nicolaus Kröger, Rainer Haas, Guido Kobbe
Journal: Blood (2012)
Hemoglobin H Hydrops Fetalis Associated with Homozygous Hemoglobin Constant Spring. Case Report.
Authors: Monica V.E. Gallivan, Emmanuel J. Vlastos, Robin D. Hanson, Maria P. Bettinoti, Steven A. Schonberg, Victoria M. Pratt, Ching-Nan Ou, Mario Mikula, Matthew J. McGinniss, Weimin Sun, Charles M. Strom
Journal: Blood (2005)
ATPS-92Bmi1 IDENTIFIES TREATMENT-REFRACTORY STEM CELLS IN HUMAN GLIOBLASTOMA
Authors: Parvez Vora, Maleeha Qazi, Chitra Venugopal, Minomi Subapanditha, David Bakhshinyan, Sujeivan Mahendram, Nicole McFarlane, Sheila Singh
Journal: Neuro-Oncology (2015)

PURPOSE: Glioblastoma (GBM) is a fatal primary adult brain tumor, characterized by extensive cellular heterogeneity.Even with surgery, chemotherapy with temozolomide (TMZ), and radiation, tumor re-growth and patient relapse are inevitable.Brain tumor initiating cells (BTICs), a rare subset of GBM cells with stem cell properties, were shown to be both chemo-and radioresistant.We hypothesize that these treatment-resistant BTICs cause tumor relapse and a subset of genes regulating BTIC self-renewal drives GBM recurrence.METHODS: Using patient-derived primary GBM samples, we designed an in vitro model of tumor recurrence by treating cells with TMZ and radiation.We then adapted the existing treatment protocol for adults with primary GBM for treatment of immunocompromised mice engrafted with GFP+ human GBM cells.Post-chemoradiotherapy, GFP+ tumor cells were recovered from mouse brains and profiled for self-renewal, proliferation and mRNA expression of important stem cell genes.Using in vitro and in vivo loss-of-function experiments, we investigated the regulatory functions of key BTIC genes in tumor formation.RESULTS: GBM cells showed an increase in Bmi1 levels post-chemoradiotherapy in vitro, suggesting the presence of a treatment-refractory BTIC population.GFP+ cells extracted from chemoradiotherapy treated human tumor xenografts showed increased self-renewal and elevated BTIC marker expression.Although treated mice responded to therapy with decreased tumor size, we observed tumor relapse postchemoradiotherapy with increased Bmi1 expression.Knockdown of Bmi1 diminished self-renewal and proliferation of GBM cells and delayed tumorigenesis in xenografted mice, highlighting a critical role for Bmi1 in tumor initiation and maintenance.CONCLUSION: Our data confirms the existence of a rare treatment-refractory BTICs population that escapes therapy, and drives tumor relapse and recurrence with enhanced self-renewal capacity.Our human BTIC in vitro assays and human-mouse BTIC xenograft model provide fundamental tools to characterize the functional relevance and of key stem cell self-renewal genes in GBM recurrence.
Severe and Prolonged Lymphopenia Observed In Patients Treated with Bendamustine and Erlotinib for Metastatic Triple Negative Breast Cancer
Authors: Rachel M Layman, Amy S Ruppert, Melinda Lynn, Ewa Mrozek, Bhuvaneswari Ramaswamy, Maryam B Lustberg, Ottman Susan, Sarah Carothers, Eric H Kraut, Charles L Shapiro
Journal: Blood (2010)
Autologous and Allogeneic Stem Cell Transplantation for T-Cell Lymphoma: The M.D. Anderson Cancer Center Experience,
Authors: Amer Beitinjaneh, Rima M. Saliba, Grace-Julia Okoroji, Martin Korbling, Amin M Alousi, Uday Popat, Paolo Anderlini, Qaiser Bashir, Borje S Andersson, Partow Kebriaei, Chitra M Hosing, Muzaffar Qazilbash, Michelle A. Fanale, Barbara Pro, Richard Champlin, Issa Khouri
Journal: Blood (2011)
Receipt of aggressive therapies for muscle-invasive bladder cancer: Results from the National Cancer Data Base.
Authors: Phillip J. Gray, Stacey A. Fedewa, William U. Shipley, Jason Alexander Efstathiou, Katherine S. Virgo, Anthony L. Zietman
Journal: Journal of Clinical Oncology (2012)

272 Background: Over 17,000 patients are diagnosed with muscle-invasive bladder cancer (MIBC) in the United States each year. Despite its lethal potential, emerging data has suggested that many patients do not receive aggressive therapy consistent with established practice standards. Using data from American College of Surgeons Commission on Cancer accredited facilities, we seek to characterize treatment patterns for patients with MIBC according to demographic, clinical, pathologic and facility variables. Methods: 28,691 adult patients diagnosed with MIBC (stages II-IV), excluding those with T4b tumors or distant metastases between 2004 and 2008 were selected for analyses from the National Cancer Database. Treatments included radical or partial cystectomy +/− chemotherapy (CT), chemoradiotherapy (CRT), radiotherapy (RT) or CT alone and surveillance. Aggressive therapy (AT) was defined as any open surgery or RT with a total dose ≥50 Gy. Determinants of AT were assessed by multivariate generalized estimating equations accounting for facility clustering. Results: 52.5% of patients received AT (45% were treated surgically while 7.5% received CRT or RT), 11.7% received palliative CT or RT, and 25.9% received surveillance only. Receipt of AT decreased significantly with advancing age (OR 0.29 for age &gt;80 vs. 18-59, p&lt;.001). AT was also received less frequently by minorities (OR 0.72 for blacks p&lt;.001), the uninsured (OR 0.72, p&lt;.001), Medicaid-insured patients (OR 0.81, p=.006) and by those patients treated at low-volume centers (OR 0.63 vs. high-volume, p&lt;.001). Receipt of AT increased with more advanced stage (OR 2.33 for stage III vs. stage II, p&lt;.001) and in patients with non-urothelial histology (OR 1.32 and 1.50 for squamous and adenocarcinoma histology respectively, p&lt;.001). Hydronephrosis was associated with decreased use of AT (OR 0.70, p&lt;.001). Conclusions: Aggressive therapies for MIBC are received less frequently by the elderly and those with historically poorer socioeconomic status. These data indicate a significant unmet clinical need for physician education regarding appropriate selection of patients for cystectomy and RT-based bladder sparing therapy.
Influence of vancomycin minimum inhibitory concentration on the outcome of methicillin-susceptible Staphylococcus aureus left-sided infective endocarditis treated with antistaphylococcal β-lactam antibiotics: a prospective cohort study by the International Collaboration on Endocarditis
Authors: J.M. Pericàs, J.A. Messina, C. Garcia-de-la-Mària, L. Park, B.K. Sharma-Kuinkel, F. Marco, D. Wray, Z.A. Kanafani, M. Carugati, E. Durante-Mangoni, P. Tattevin, V.H. Chu, A. Moreno, V.G. Fowler, J.M. Miró, E. Athan, O. Harris, T.M. Korman, D. Kotsanas, P. Jones, P. Reinbott, S. Ryan, C.Q. Fortes, P. Garcia, S.B. Jones, B. Barsic, S. Bukovski, C. Selton-Suty, N. Aissa, T. Doco-Lecompte, F. Delahaye, F. Vandenesch, P. Tattevin, B. Hoen, P. Plesiat, H. Giamarellou, E. Giannitsioti, E. Tarpatzi, E. Durante-Mangoni, D. Iossa, S. Orlando, M.P. Ursi, P.C. Pafundi, F. D' Amico, M. Bernardo, S. Cuccurullo, G. Dialetto, F.E. Covino, S. Manduca, A. Della Corte, M. De Feo, M.F. Tripodi, T. Baban, Z.A. Kanafani, S.S. Kanj, J. Sfeir, M. Yasmine, A. Morris, D.R. Murdoch, M.M. Premru, T. Lejko-Zupanc, M. Almela, J. Ambrosioni, M. Azqueta, M. Brunet, C. Cervera, E. De Lazzari, C. Falces, D. Fuster, C. Garcia-de-la-Mària, J. Garcia-Gonzalez, J.M. Gatell, F. Marco, J.M. Miró, A. Moreno, J. Ortiz, S. Ninot, J.C. Paré, J.M. Pericas, E. Quintana, J. Ramirez, E. Sandoval, M. Sitges, J.M. Tolosana, B. Vidal, J. Vila, E. Bouza, P. Muñoz, M. Rodríguez-Créixems, V. Ramallo, S. Bradley, D. Wray, L. Steed, R. Cantey, G. Peterson, A. Stancoven, C. Woods, G.R. Corey, L.B. Reller, V.G. Fowler, V.H. Chu, K. Baloch, V.H. Chu, G.R. Corey, C.C. Dixon, V.G. Fowler, T. Harding, M. Jones-Richmond, P. Pappas, L.P. Park, T. Redick, J. Stafford, K. Anstrom, E. Athan, A.S. Bayer, C.H. Cabell, V.H. Chu, G.R. Corey, V.G. Fowler, B. Hoen, A.W. Karchmer, J.M. Miró, D.R. Murdoch, D.J. Sexton, A. Wang, A.S. Bayer, C.H. Cabell, V. Chu, G.R. Corey, D.T. Durack, S. Eykyn, V.G. Fowler, B. Hoen, J.M. Miró, P. Moreillon, L. Olaison, D. Raoult, E. Rubinstein, D.J. Sexton
Journal: Clinical Microbiology and Infection (2017)
Osteonecrosis of the Jaw or Maxilla after Intravenous Bisphosphonates for Multiple Myeloma and Breast Cancer: Long-Term Follow-Up Shows a Slow Rate of Healing.
Authors: Mimi I. Hu, Ana O. Hoff, Bela Toth, K. Altundag, Marcella Johnson, Carla Warneke, Ajay Nooka, Gilbert Sayegh, Valentina Guarneri, Kimberly Desrouleaux, Cui Jeffrey, Gabriel N. Hortobagyi, Robert F. Gagel
Journal: Blood (2006)
The Hbo1-Brd1/Brpf2 HAT Complex Is Required for Erythropoiesis In Fetal Liver
Authors: Yuta Mishima, Satoru Miyagi, Atsunori Saraya, Masamitsu Negishi, Mitsuhiro Endoh, Naoto Yamaguchi, Issay Kitabayashi, Haruhiko Koseki, Atsushi Iwama
Journal: Blood (2010)
Consolidative high-dose chemotherapy (HDCT) after conventional-dose chemotherapy (CDCT) as first salvage treatment for male patients (pts) with metastatic germ cell tumors (mGCTs).
Authors: Michel S Beausoleil, Kylea R. Potvin, Kang Howson-Jan, D. Scott Ernst, Larry Stitt, Eric Winquist
Journal: Journal of Clinical Oncology (2012)

336 Background: Some men with mGCTs progressing after response to initial cisplatin-based combination chemotherapy are cured with CDCT as 1st salvage, however, many are not. Prognosis has recently been better defined by the IPFSG prognostic factors. HDCT with autologous stem cell rescue has been routinely offered after CR/PRm- remission with CDCT at our institution over the past two decades. We retrospectively reviewed our data to assess the validity of the IPFSG prognostic factors and evaluate the potential value of this approach. Methods: Eligible men with mGCTs progressing after at least 3 cycles of cisplatin-based chemotherapy received after 01 Jan 1990 and treated with cisplatin-based CDCT+/−HDCT (etoposide + carboplatin) were identified and data collected. Pts were classified into risk groups using IPFSG factors, PFS and OS were analyzed and results for CDCT+/−HDCT compared. Results: 38 eligible 1st salvage pts had received a median of 4 cycles (range, 1–7) of CDCT. 20 pts received CDCT alone &amp; 18 pts received CDCT+HDCT. Overall median PFS was 24.6 months (95%CI, 7.3–28.7) and overall median OS was 34.6 months (95%CI, 17.2–51.3). Distribution by IPFSG category, 2-year PFS and 3-year OS rates within each risk category were very similar to IPFSG results. Two toxic deaths occurred with CDCT. Pts treated with CDCT+HDCT more often had better responses to 1st-line chemotherapy and pure seminoma histology. Overall pts treated with CDCT+HDCT had improved PFS (HR: 0.18; 95%CI, 0.07–0.51; p=0.001) and OS (HR: 0.25; 95%CI, 0.10–0.65; p=0.004) compared to CDCT alone. Examination by IPFSG risk category showed that the 2-year PFS and 3-year OS rates for CDCT+HDCT was higher in all prognostic groups except for the very high risk which did not have any HDCT pts. Conclusions: The IPFSG prognostic factors were valid in our 1st salvage mGCT pts. The safety of HDCT with etoposide and carboplatin was confirmed. HDCT was associated with improved PFS and OS outcomes, consistent with observations of Lorch et al (JCO 2011). Ideally the value of optimal CDCT+HDCT should be determined in comparison to optimal CDCT as first salvage therapy in men with metastatic GCT in a randomized trial.
STEM-08INHIBITION OF THE NEURAL STEM CELL/OLIGODENDROCYTE PROGENITOR FACTOR GPR56 PROMOTES THE PRONEURAL TO MESENCHYMAL TRANSITION AND RADIORESISTANCE IN GLIOBLASTOMA
Authors: Marta Moreno, Estela Pineda, Josefina Martínez, Leire Bejarano, Veerakumar Balasubramaniyan, Ravesanker Ezhilarasan, Naveen Kallarackal, Sung-Hak Kim, Laia Paré, Avelina Tortosa, Candelaria Gómez-Manzano, Francesc Graus, Erik Sulman, Xianhua Piao, Ichiro Nakano, Aleix Prat, Krishna Bhat, Nuria de la Iglesia
Journal: Neuro-Oncology (2015)

A proneural-to-mesenchymal transition (PMT) is thought to occur during natural evolution of glioblastoma (GBM) as well as in response to therapy, specifically during acquisition of radioresistance. In order to identify novel inhibitors of PMT, we searched for factors enriched in neural stem cells (NSCs) and/or oligodendrocyte progenitor cells (OPCs) and whose function might be related to the maintenance of epithelial features, such as cell adhesion and inhibition of migration. GPR56 is an adhesion receptor highly expressed in NSCs, where it mediates the attachment of radial glial progenitors to the pial basement membrane. This receptor inhibits the migration of NSCs and invasion and metastasis in some cancers, thereby suggesting it might have a functional role in counteracting an EMT-like process. Here, we report that GPR56 is enriched in PN-GBMs and lost during their transition towards a MES subtype. Inhibition of GPR56 promotes MES differentiation and radioresistance of glioma stem-like initiating cells (GICs) both in vitro and in vivo. Mechanistically, we identify GPR56 as a novel inhibitor of the NF-κB signaling pathway, thereby providing the rationale by which this receptor prevents PMT. Furthermore, we show that low GPR56 activity is a poor prognostic factor in GBM, even within non-G-CIMP GBMs. Therefore, by studying the role of a factor that is intimately linked to the biology of the cell-of-origin of GBM, we have identified a molecular signature with independent prognostic value in non-G-CIMP GBMs. Our results suggest that functional signatures may have stronger prognostic value than phenotypic signatures and provide a new molecular mechanism underlying radioresistance in GBM. Ultimately, a pan-cancer analysis suggests that GPR56 might be an inhibitor of the MES transition across multiple tumor types beyond GBM.
DEK/NUP214 Fusion Gene Predicts Good Outcome In Acute Myeloid Leukemia In Complete Remission After Allogeneic Hematopoietic Stem Cell Transplantation
Authors: Ken Ishiyama, Akiyoshi Takami, Shinji Nakao, Michihiro Hidaka, Tetsuo Maeda, Keisei Kawa, Tokiko Nagamura, Ken Tabuchi, Yoshiko Atsuta, Hisashi Sakamaki
Journal: Blood (2010)